Related Experiment Video

Updated: Jun 17, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation

Donghwa Kim1, Mei Sun, Lili He

  • 1Departments of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

The Journal of Biological Chemistry
|January 14, 2010
PubMed

Insights

A novel small molecule, API-1, inhibits the Akt pathway by blocking its membrane translocation. API-1 demonstrates anti-tumor activity in vitro and in vivo, offering potential for treating cancers with hyperactivated Akt signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Akt pathway is frequently hyperactivated in human cancers, acting as a key regulator of oncogenic signals.
  • This pathway presents a promising target for novel molecular therapeutics in cancer treatment.

Purpose of the Study:

  • To identify and characterize a novel small molecule inhibitor of the Akt pathway.
  • To evaluate the efficacy of this inhibitor, API-1, as a potential anti-cancer agent.

Main Methods:

  • API-1 was identified as a small molecule inhibitor targeting the pleckstrin homology domain of Akt.
  • The study assessed API-1's effects on Akt kinase activity, membrane translocation, and phosphorylation in cancer cells.
  • In vivo studies evaluated API-1's anti-tumor efficacy in mouse models.

Main Results:

  • API-1 binds to the Akt pleckstrin homology domain, inhibiting Akt membrane translocation and downstream kinase activity.
  • API-1 selectively inhibited constitutively active Akt, including AKT1-E17K, without affecting upstream activators or other kinases.
  • API-1 induced cell growth arrest and apoptosis in cancer cells with hyperactivated Akt and reduced tumor growth in vivo.

Conclusions:

  • API-1 is a direct Akt inhibitor that blocks its membrane translocation.
  • API-1 exhibits selective anti-cancer activity in vitro and in vivo, particularly in tumors with elevated Akt.
  • API-1 represents a potential therapeutic agent for Akt-driven cancers.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...